Given the crucial involvement of NF-κB in the pathophysiological mechanisms underlying various aspects of DCM, it is reasonable to hypothesize that external manipulation of NF-κB activation could prove efficacious in the development of novel therapeutic interventions. This evidence concerns the gene NFKB1 and familial dilated cardiomyopathy.